
Vitalgen’s Gene Therapy Drug VGN-R09b for Primary Parkinson’s Disease Receives FDA Fast Track Designation
SHANGHAI, CHINA, June 30, 2025 /EINPresswire.com/ -- Shanghai Vitalgen BioPharma Co., Ltd. ("Vitalgen") announced that its gene therapy drug, VGN-R09b, for the treatment of Primary Parkinson’s Disease (PD), has received Fast Track …